The fibrinolytic potential in patients with Cushing's disease: a clue to their hypercoagulable state.
The aim of our study was to determine the fibrinolytic potential in a large group of patients with Cushing's disease. These patients had a significant shortening of the activated partial thromboplastin time and increase in factor VIII/von Willebrand factor complex compared to normal controls. The mean levels of plasminogen, tissue plasminogen activator (t-PA) antigen and plasminogen activator inhibitor (PAI) activity were significantly higher than in normal subjects, whereas the basal fibrinolytic activity was similar to that seen in the control group. In 17 out of 30 Cushing patients and in 17 normal subjects the fibrinolytic potential was determined with the venous occlusion test. In the Cushing group, the release of t-PA antigen after 20 min of venous occlusion was comparable to that observed in the control group. However, Cushing patients showed a lower fibrinolytic activity than normal subjects, since a lesser shortening of the euglobulin lysis time and a non-significant rise of plasminogen activator activity levels were found. Moreover, in these patients the PAI activity values remained unchanged and significantly increased after venous occlusion test also. In conclusion, the impaired fibrinolytic activation seen in Cushing patients after venous occlusion can be explained by the inhibitory effect of the high PAI levels on plasminogen activators. The defective fibrinolytic potential could further contribute to the hypercoagulable state in Cushing's disease. High PAI levels before surgery may represent an additional risk factor for post-surgical thromboembolic complications in Cushing patients.
Patrassi
G M
GM
Institute of Medical Semeiotics, University of Padua Medical School, Italy.
Sartori
M T
MT
Viero
M L
ML
Scarano
L
L
Boscaro
M
M
Girolami
A
A
D000328:Adult; D001778:Blood Coagulation Disorders / Q000209:etiology*; D003250:Constriction; D003480:Cushing Syndrome / Q000097:blood* / Q000150:complications; D005169:Factor VIII / Q000032:analysis; D005260:Female; D005342:Fibrinolysis; D006801:Humans; D008297:Male; D010314:Partial Thromboplastin Time; D010958:Plasminogen / Q000032:analysis; D017395:Plasminogen Activator Inhibitor 1 / Q000032:analysis; D010959:Tissue Plasminogen Activator / Q000032:analysis; D014680:Veins; D014841:von Willebrand Factor / Q000032:analysis
D017395:Plasminogen Activator Inhibitor 1; D014841:von Willebrand Factor; D005169:Factor VIII; D010958:Plasminogen; D010959:Tissue Plasminogen Activator